PMN-310

ProMIS Neurosciences has begun a Phase 1b clinical trial (PRECISE-AD) to evaluate PMN310 for Alzheimer's, targeting toxic amyloid-beta oligomers.

PMN310, a monoclonal antibody targeting toxic amyloid beta oligomers, was well-tolerated in a Phase 1a trial with healthy volunteers.

ProMIS Neurosciences presented Phase 1a clinical trial data for PMN310, indicating it was generally well-tolerated in healthy volunteers.

ProMIS Neurosciences has begun dosing subjects in a Phase 1a clinical trial for PMN310, a novel monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease, marking a significant step towards developing a new treatment.